ATE496045T1 - Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase - Google Patents

Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase

Info

Publication number
ATE496045T1
ATE496045T1 AT08736964T AT08736964T ATE496045T1 AT E496045 T1 ATE496045 T1 AT E496045T1 AT 08736964 T AT08736964 T AT 08736964T AT 08736964 T AT08736964 T AT 08736964T AT E496045 T1 ATE496045 T1 AT E496045T1
Authority
AT
Austria
Prior art keywords
disorders
kinase
inhibitors
phosphatidylinositol
pyrimidine derivatives
Prior art date
Application number
AT08736964T
Other languages
English (en)
Inventor
Paul Goldsmith
Timothy Hancox
Neil Pegg
Stephen Shuttleworth
Elsa Dechaux
Stephen Price
Jonathan Large
Edward Mcdonald
Original Assignee
Hoffmann La Roche
Cancer Res Inst Royal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707088A external-priority patent/GB0707088D0/en
Priority claimed from GB0707611A external-priority patent/GB0707611D0/en
Application filed by Hoffmann La Roche, Cancer Res Inst Royal filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE496045T1 publication Critical patent/ATE496045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
AT08736964T 2007-04-12 2008-04-14 Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase ATE496045T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707088A GB0707088D0 (en) 2007-04-12 2007-04-12 Pharmaceutical compounds
GB0707611A GB0707611D0 (en) 2007-04-19 2007-04-19 Pharmaceutical compounds
PCT/GB2008/001301 WO2008125839A2 (en) 2007-04-12 2008-04-14 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase

Publications (1)

Publication Number Publication Date
ATE496045T1 true ATE496045T1 (de) 2011-02-15

Family

ID=39832798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08736964T ATE496045T1 (de) 2007-04-12 2008-04-14 Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase

Country Status (13)

Country Link
US (1) US20100130496A1 (de)
EP (1) EP2150546B1 (de)
JP (1) JP2010523639A (de)
KR (1) KR20100016433A (de)
CN (1) CN101765597A (de)
AT (1) ATE496045T1 (de)
AU (1) AU2008237721A1 (de)
BR (1) BRPI0810641A2 (de)
CA (1) CA2683624A1 (de)
DE (1) DE602008004650D1 (de)
IL (1) IL201365A0 (de)
MX (1) MX2009010886A (de)
WO (1) WO2008125839A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008125833A1 (en) * 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
KR20110046514A (ko) 2008-07-31 2011-05-04 제넨테크, 인크. 피리미딘 화합물, 조성물 및 사용 방법
JP5555236B2 (ja) * 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
KR20110120286A (ko) 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체
JP5572715B2 (ja) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
CN102711766B (zh) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-取代的嘌呤化合物、组合物和使用方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5765342B2 (ja) 2010-08-10 2015-08-19 アステラス製薬株式会社 へテロ環化合物
AU2011310592B2 (en) 2010-09-29 2015-01-22 Intervet International B.V. N-heteroaryl compounds
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
EP2790705B1 (de) 2011-12-15 2017-12-06 Novartis AG Verwendung von inhibitoren der aktivität oder funktion von pi3k
EP2831042B1 (de) 2012-03-28 2019-07-31 Intervet International B.V. Heteroaryl-verbindungen mit azyklischer brückeneinheit
KR20160027217A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
KR102314669B1 (ko) * 2013-11-15 2021-10-18 바이엘 크롭사이언스 악티엔게젤샤프트 니트릴의 촉매 수소화
CN114634483A (zh) 2014-02-21 2022-06-17 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN110291069A (zh) 2016-12-21 2019-09-27 拜耳农作物科学股份公司 腈的催化氢化
WO2018213211A1 (en) * 2017-05-15 2018-11-22 The Regents Of The University Of Michigan Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
EP3967694A4 (de) * 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. 2, 4, 6-tri-substituierte pyrimidinverbindung als atr-kinase-inhibitor
JP2023505485A (ja) 2019-12-04 2023-02-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ａｔｍキナーゼ阻害剤及び組成物並びにそれらの使用の方法
CA3171187A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Inhibitors of ulk1/2 and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083456A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses
EP2316831B1 (de) * 2002-11-21 2013-03-06 Novartis AG 2-(morpholin-4-yl)Pyrimidinen als Phosphotidylinositol (PI) 3-Kinase Inhibitoren und deren Verwendung zur Behandlung von Krebs
CA2527079A1 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
AU2005244104B2 (en) * 2004-05-08 2012-03-15 Novartis International Pharmaceutical Ltd. 4,5-disubstituted-2-aryl pyrimidines
WO2006060194A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
KR20100016433A (ko) 2010-02-12
MX2009010886A (es) 2009-12-14
CN101765597A (zh) 2010-06-30
EP2150546B1 (de) 2011-01-19
US20100130496A1 (en) 2010-05-27
WO2008125839A3 (en) 2008-12-24
JP2010523639A (ja) 2010-07-15
WO2008125839A2 (en) 2008-10-23
IL201365A0 (en) 2010-05-31
AU2008237721A1 (en) 2008-10-23
EP2150546A2 (de) 2010-02-10
BRPI0810641A2 (pt) 2019-09-24
DE602008004650D1 (de) 2011-03-03
CA2683624A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
ATE496045T1 (de) Pyrimidinderivate als inhibitoren von phosphatidylinositol-3-kinase
MX2009010881A (es) Compuestos farmaceuticos.
GB0423653D0 (en) Pharmaceutical compounds
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
WO2009053715A8 (en) Thienopyrimidiene derivatives as pi3k inhibitors
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
EP4104837A3 (de) Heterocyclische verbindungen als ret kinase hemmer
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE549336T1 (de) Heteroarylverbindungen,zusammensetzungen daraus und ihre verwendung als proteinkinasehemmer
NZ592925A (en) Substituted pyrimidines for the treatment of diseases such as cancer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2012002480A (es) Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
AU2011269989A8 (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
NO20090580L (no) Syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
AU2009282962A8 (en) Compounds as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties